<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papadimitriou, C.A.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Aravantinos, G.</style></author><author><style face="normal" font="default" size="100%">Kalofonos, C.</style></author><author><style face="normal" font="default" size="100%">Moulopoulos, L.A.</style></author><author><style face="normal" font="default" size="100%">Briassoulis, E.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group Study</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Carboplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Gemcitabine</style></keyword><keyword><style  face="normal" font="default" size="100%">Platinum-sensitive relapsed ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Second-line chemotherapy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0742289996&amp;doi=10.1016%2fj.ygyno.2003.09.021&amp;partnerID=40&amp;md5=2c0c6b77fd296fff37cdf9160ed85a04</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">92</style></volume><pages><style face="normal" font="default" size="100%">152 - 159</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objective. Patients with epithelial ovarian cancer (EOC) who relapse more than 6 months following completion of platinum-based primary chemotherapy are considered platinum-sensitive, and can be effectively retreated with cisplatin or carboplatin. The nucleoside analogue gemcitabine has proven activity in both platinum-sensitive and platinum-resistant disease. We conducted a phase II study using the combination of carboplatin and gemcitabine for the treatment of patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC. Methods. Forty-three patients were treated with gemcitabine 1000 mg/m 2, intravenously, over 30 min on days 1 and 8, and carboplatin at AUC 5 on day 1. Courses were administered every 3 weeks on an outpatient basis. Results. Among 37 patients with measurable or evaluable disease, 15 (40.5%) achieved an objective response including 10 complete and 5 partial responses. The median overall survival was 24.5 months, and the median time to progression for all patients was 9 months. The treatment was well tolerated without toxic deaths; the most common toxicities were Grade 3 or 4 neutropenia, anemia, and thrombocytopenia that occurred in 69%, 26%, and 24% of patients, respectively. Conclusions. The combination of carboplatin and gemcitabine is a well-tolerated outpatient regimen with activity in patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC. However, a randomized prospective study is justified to define whether the addition of gemcitabine to single-agent carboplatin results in improved efficacy in this subset of patients. © 2003 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :30Export Date: 21 February 2017</style></notes></record></records></xml>